Plasma kallikrein: The bradykinin-producing enzyme

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 399-407

  Björkqvist, Jenny ^a   Jämsä, Anne ^a   Renné, Thomas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANGIOTENSIN I; ANGIOTENSIN II; ANTIFIBRINOLYTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBIN III; APROTININ; CALCIUM ION; CARBONATE DEHYDRATASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; DIPEPTIDYL CARBOXYPEPTIDASE; DYFLOS; ECALLANTIDE; HEAT SHOCK PROTEIN 90; HEPARAN; INTERLEUKIN 1BETA; KALLIKREIN; KALLIKREIN INHIBITOR; P AMIDINOPHENYLMETHYLSULFONYLFLUORIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN KINASE C; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE;

ANGIONEUROTIC EDEMA; ARTICLE; BIOCHEMISTRY; BLEEDING; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; COMPLEMENT ALTERNATIVE PATHWAY; CYTOLOGY; DEATH; DIABETIC RETINOPATHY; ENZYME ACTIVITY; FIBRINOLYSIS; GENE STRUCTURE; HEMATOMA; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; INFLAMMATORY DISEASE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULITIS;

ANIMALS; APROTININ; BLOOD COAGULATION; BRADYKININ; CEREBRAL HEMORRHAGE; COMPLEMENT SYSTEM PROTEINS; CYSTEINE; DIABETIC RETINOPATHY; DISULFIDES; FACTOR XIIA; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INFLAMMATION; KALLIKREIN-KININ SYSTEM; KALLIKREINS; KININS; MICE; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; PLASMA KALLIKREIN; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; THROMBOSIS; TRYPSIN;

EID: 84883216057     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0258     Document Type: Article

References (89)

1. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
2. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012; 22: 4296-4303.
3. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
4. Chung DW, Fujikawa K, McMullen BA, et al. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-2417.
5. Renne T, Gailani D, Meijers JC, et al. Characterisation of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem 2002; 277: 4892-4899.
6. Herwald H, Jahnen-Dechent W, Alla SA, et al. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain. J Biol Chem 1993; 268: 14527-14535.
7. Renne T, Dedio J, Meijers JC, et al. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999; 274: 25777-25784.
8. Colman RW, Wachtfogel YT, Kucich U, et al. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 1985; 65: 311-318.
9. Neth P, Arnhold M, Sidarovich V, et al. Expression of the plasma prekallikrein gene: utilisation of multiple transcription start sites and alternative promoter regions. Biol Chem 2005; 386: 101-109.
10. Fujikawa K, Chung DW, Hendrickson LE, et al. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-2424.
11. Tordai H, Banyai L, Patthy L. The PAN module: the N-terminal domains of plasminogen and hepatocyte growth factor are homologous with the apple domains of the prekallikrein family and with a novel domain found in numerous nematode proteins. FEBS Lett 1999; 461: 63-67.
12. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-1883.
13. Girolami A, Scarparo P, Candeo N, et al. Congenital prekallikrein deficiency. Expert Rev Hematol 2010; 3: 685-695.
14. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
15. Wuepper KD. Prekallikrein deficiency in man. J Exp Med 1973; 138: 1345-1355.
16. Abildgaard CF, Harrison J. Fletcher factor deficiency: family study and detection. Blood 1974; 43: 641-644.
17. LaDuca FM, Tourbaf KD. Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am J Clin Pathol 1981; 75: 626-628.
18. Revak SD, Cochrane CG, Johnston AR, et al. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-627.
19. Fujikawa K, Heimark RL, Kurachi K, et al. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 1980; 19: 1322-1330.
20. Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175.
21. Cochrane CG, Griffin JH. Molecular assembly in the contact phase of the Hageman factor system. Am J Med 1979; 67: 657-664.
22. Tans G, Rosing J, Berrettini M, et al. Autoactivation of human plasma prekallikrein. J Biol Chem 1987; 262: 11308-11314.
23. van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158.
24. Berrettini M, Schleef RR, Espana F, et al. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989; 264: 11738-11743.
25. Meijers JC, Kanters DH, Vlooswijk RA, et al. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237.
26. Reddigari SR, Shibayama Y, Brunnee T, et al. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-11987.
27. Motta G, Rojkjaer R, Hasan AA, et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-528.
28. Meloni FJ, Gustafson EJ, Schmaier AH. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 1992; 79: 1233-1244.
29. Gustafson EJ, Schmaier AH, Wachtfogel YT, et al. Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest 1989; 84: 28-35.
30. Renne T, Dedio J, David G, et al. High molecular weight kininogen utilises heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-33696.
31. Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 2001; 500: 36-40.
32. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-3385.
33. Joseph K, Ghebrehiwet B, Peerschke EI, et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci USA 1996; 93: 8552-8557.
34. Mahdi F, Madar ZS, Figueroa CD, et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-3596.
35. Dembitzer FR, Kinoshita Y, Burstein D, et al. gC1qR expression in normal and pathologic human tissues: differential expression in tissues of epithelial and mesenchymal origin. J Histochem Cytochem 2012; 60: 467-474.
36. Dedio J, Jahnen-Dechent W, Bachmann M, et al. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol 1998; 160: 3534-3542.
37. Maas C, Renne T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012; 129 (Suppl 2): S73-76.
38. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-381.
39. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
40. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268.
41. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-3218.
42. Muller F, Renne T. Platelet polyphosphates: The nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 2011; 71: 82-86.
43. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, et al. Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem 2012; 287: 28435-28444.
44. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
45. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98: 497-502.
46. Soisson SM, Patel SB, Abeywickrema PD, et al. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct Biol 2010; 10: 16.
47. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterisation of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-17969.
48. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyses activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900.
49. Goetzl EJ, Austen KF. Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest 1974; 53: 591-599.
50. Becker CG, Dubin T, Glenn F. Induction of acute cholecystitis by activation of factor XII. J Exp Med 1980; 151: 81-90.
51. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
52. Schapira M, Despland E, Scott CF, et al. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-1202.
53. Benz PM, Blume C, Seifert S, et al. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci 2009; 122: 3954-3965.
54. Blume C, Benz PM, Walter U, et al. AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J Biol Chem 2007; 282: 4601-4612.
55. Benz PM, Blume C, Moebius J, et al. Cytoskeleton assembly at endothelial cellcell contacts is regulated by alphaII-spectrin-VASP complexes. J Cell Biol 2008; 180: 205-219.
56. Tiruppathi C, Ahmmed GU, Vogel SM, et al. Ca2+ signalling, TRP channels, and endothelial permeability. Microcirculation 2006; 13: 693-708.
57. Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci 2003; 24: 24-29.
58. Lindsay SL, Ramsey S, Aitchison M, et al. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J Cell Sci 2007; 120: 3011-3021.
59. Wojciak-Stothard B, Torondel B, Zhao L, et al. Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol Biol Cell 2009; 20: 33-42.
60. Shigematsu S, Ishida S, Gute DC, et al. Bradykinin-induced proinflammatory signalling mechanisms. Am J Physiol Heart Circ Physiol 2002; 283: H2676-2686.
61. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-374.
62. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-2513.
63. Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
64. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969; 35: 273-279.
65. Jorg M, Binder BR. Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb Res 1985; 39: 323-331.
66. Derkx FH, Bouma BN, Schalekamp MP, et al. An intrinsic factor XII-prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 1979; 280: 315-316.
67. Sealey JE, Atlas SA, Laragh JH, et al. Activation of a prorenin-like substance in human plasma by trypsin and by urinary kallikrein. Hypertension 1979; 1: 179-189.
68. Kaplan AP, Ghebrehiwet B, Silverberg M, et al. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships. Crit Rev Immunol 1981; 3: 75-93.
69. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45: 587-595.
70. Davis AE, 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl 2): S7-12.
71. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
72. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
73. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063.
74. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-3218.
75. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002; 347: 621-622.
76. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
77. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates haemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13: 181-188.
78. Gao BB, Chen X, Timothy N, et al. Characterisation of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 2008; 7: 2516-2525.
79. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
80. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011; 17: 206-210.
81. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
82. Bird JE, Smith PL, Wang X, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150.
83. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
84. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
85. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.
86. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
87. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331.
88. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29: 255-258.
89. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies physicochemical properties. Blood 1965; 26: 521-532.